To help pharmacy owner to better understand the negotiating process, Community Pharmacy England (CPE) has published commentary and infographics.
"Our work to negotiate fair funding, as well as changes to NHS pharmacy services, with the Department of Health and Social Care (DHSC) and NHS England is a
crucial part of our role," said CPE.
"Understandably the sector is eagerly awaiting an update on the progress of the current negotiations on the Government's pledge to invest £645m in community
pharmacies and, as part of our ongoing efforts to improve transparency of our work, we have released materials to explain the negotiating process."
Negotiating Team Member Stephen Thomas - who joined the team this year - has written a blog about his experiences.
He has described both the complexity of the process and volume of work undertaken, and recognises the significance of his role on behalf of pharmacy owners across
the country.
Whilst speed is of the essence, even higher on the Negotiating Team's list of priorities is working through a large number of important questions - particularly
around the funding and logistics that need to be put in place.
The British Generic Manufacturers Association (BGMA) has sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a
new Voluntary Scheme for branded medicines with the Association of the British Pharmaceutical Industry (ABPI).
Mark Samuels, Chief Executive of BGMA said: "The Government has decided not to involve the trade body representing these medicine suppliers in its negotiations on the
voluntary scheme for branded medicine pricing (VPAS).
"We are deeply concerned by this decision. It has left us no choice but to take legal action."
"While not all generic drugs fall within VPAS, four out of ten products in the current scheme are branded generics or biosimilars. As the representative trade body
for both generic and biosimilar UK manufacturers, we must play a full part in the VPAS negotiations for the next period of the scheme from 2024 to 2028."
"The VPAS tax has risen five-fold in under two years, an unprecedented tax increase. Yet our sector currently has no input into the negotiations on future schemes or
rates; this is untenable as any decisions made on VPAS could significantly define the future of our sector in the UK and its ability to supply the NHS.
The association had raised its full participation in the negotiations with the Government last November.
Pharmaceutical Services Negotiating Committee expects the next round of negotiations to set the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2022/23 - Year 4 of the five-year CPCF deal, to begin soon.
The negotiator held a meeting on November 24 and 25 to discuss the burning issues affecting the sector and to plan for upcoming negotiations with the Department of Health and Social Care (DHSC) and NHS England and NHS Improvement (NHSE&I).
It aims to complete these negotiations by April, allowing ample time for contractors to make arrangement prior to the beginning of the financial year.
PSNC vice-chair, and independent contractor, Bharat Patel said the entire sector is worried about the "outlook for pharmacies as we head into a difficult winter," and is working to find solutions.
He noted that PSNC "will be bringing proposals for additional funding and support, particularly around the treatment of 'walk-in' patients, to the table, along with a heavy dose of realism for government and the NHS about the current challenges in the sector."
While expecting a difficult round of discussion with the government, Patel remained optimistic about a favourable outcome for pharmacies.
The Pharmaceutical Services Negotiating Committee (PSNC) has published an update on the work it is doing as part of the Transforming Pharmacy Representation
(TAPR) Programme to take forward the mandate from contractors to deliver the Review Steering Group (RSG) recommendations.
The update is primarily aimed at LPCs - with whom PSNC has been working closely on some of the TAPR work over the summer.
The TAPR Programme is being undertaken in support of PSNC's work to address the severe challenges facing the community pharmacy sector at present.
Alongside ongoing negotiations with Government and the NHS, two of the TAPR workstreams - focusing on Vision and Strategy, and on Influencing and Negotiation - are
essential to supporting CPCF negotiations.
"The workstreams are looking at the future of community pharmacy and how best to persuade policymakers to implement a shared vision, with their objective being to put
the sector in a stronger position going into future CPCF negotiations," said PSNC.
A full CPE Committee Meeting was organised in London on April 17 and 18, 2024, to discuss crucial sectoral issues.
Key topics discussed during the two-day meeting included intolerable pressures on pharmacy owners, the ongoing Community Pharmacy Contractual Framework (CPCF)
negotiations, implementation of the Pharmacy First service, and governance changes.
Committee Members reviewed the progress of CPCF negotiations with the Department of Health and Social Care (DHSC) and NHS England. These critical negotiations
are being led by the Negotiating Team (NT), which includes independent pharmacy owners and representatives of CCA and non-CCA multiples.
The CPE has been advocating for an uplift to the core global sum, margin write-offs, an agreed mechanism for regular funding increases linked to activity and
inflation, annual uplifts to service fees, more fundamental reform of the margin delivery framework and an economic review of the medicines supply chain.
The Committee also discussed the results of the 2024 Pharmacy Pressures Survey, which was conducted during March and April.
The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government
and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS).
The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines
with the Association of the British Pharmaceutical Industry (ABPI) in April.
Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body
for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's
judgment.
"While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the
industry from the surge in the branded medicine payment rates.
"The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in
line with comparator countries to unlock investment and growth."
The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for
branded medicines pricing on Thursday (4 May).
A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023
In their first meeting, the government, NHS England and industry - represented by the ABPI -expected to agree to a shared negotiation aim of working toward a
mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth.
Health Minister, Will Quince, said: "These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our
health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times - one of the Prime Minister's 5 priorities.
The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life
sciences sector.
The Pharmaceutical Services Negotiating Committee (PSNC) has commissioned Nuffield Trust and The King's Fund to develop a new vision and strategic options for
community pharmacy.
The report is expected to be published in early summer next year, to underpin the future strategy for the sector. It will also support negotiations between PSNC
and policymakers as the current five-year Community Pharmacy Contractual Framework (CPCF) comes to an end.
Those negotiations will decide what happens after April 2024, and they will be critical to the future of the sector.
The development of a compelling vision and an effective strategy for community pharmacy was a key recommendation from the Pharmacy Representation Review Steering
Group (RSG). It forms one of the workstreams of the Transforming Pharmacy Representation Programme (TAPR) currently being undertaken by PSNC. But it is also a project
that PSNC wants to undertake anyway to help lay the foundations for those crucial upcoming negotiations.
The Pharmaceutical Services Negotiating Committee (PSNC) has refused to accept the Department of Health and Social Care (DHSC)'s decision to get rid of
'transitional payments' from February 2023.
The pharmacy negotiator said that 'any reductions in payments at this point will be impossible for community pharmacy contractors to manage financially.'
"We are also continuing to be clear with officials and ministers that CPCF funding needs an urgent uplift to help businesses to cope with soaring costs being driven
by inflation and the workforce crisis. We put a comprehensive business case to the government for this uplift in the last CPCF negotiations."
The latest 'transitional payments decision' by the Department follows the announcement last year that the value of the these payments would be phased down over the
second half of 2022/23 and will be based on the latest monitoring and analysis of funding delivery.
PSNC says it submitted a fully-costed bid for a 'Pharmacy First' service in its last round of negotiations alongside the case for an uplift to core CPCF funding.
Both of these were refused.
The Pharmaceutical Services Negotiating Committee (PSNC) has expressed disappointment as the government continued to refuse to "a much-needed broader funding uplift" for the community pharmacies in England.
This follows conclusion of the first Annual Review of the progress of the five-year Community Pharmacy Contractual Framework (CPCF) deal by PSNC, the Department of Health and Social Care (DHSC) and NHS England & NHS Improvement (NHSE&I).
"We remain deeply frustrated by government's refusal to agree a much-needed broader funding uplift for the sector, but we are determined to continue to look for
better ways forward for the sector throughout 2022 and beyond," said Bharat Patel, PSNC vice-chair, negotiating team member and an independent contractor.
Patel noted that despite some important wins such as recognition of key challenges faced by pharmacies, the commitment to consider these as part of our Year 4
negotiations, and agreement to take forward work on service fee and other regulatory changes, the PSNC is disappointed that the review did not lead to "immediate and tangible outcomes and improvements for contractors."
The negotiator had put forward data and analysis showing the capacity and cost constraints faced by pharmacies.
The Pharmaceutical Services Negotiating Committee (PSNC) has called the 'new general practice contract' which was imposed by NHS England on Monday (6 March)
as 'simply unreasonable'.
The imposition of new contract followed a failed talk of British Medical Association (BMA)'s with the negotiator. The association's main issue with the contract is
the lack of further funding beyond that agreed in 2019 as part of the five-year deal.
PSNC Chief Executive Janet Morrison said: "The breakdown in GP contract negotiations for the second year running is another blow for primary care. The verdict of the
GP negotiators is that the demands being made of doctors by Government and the NHS are simply unreasonable."
"Community pharmacy is being treated with the same disregard: too much is being asked of us, with far too little funding available."
The committee has been raising the issue and challenges faced by the community pharmacists with the government. The government is asking pharmacies to do more by
taking giving additional services but the committee is of view with no extra funding the community pharmacies will collapse.
Community Pharmacy England (CPE) is aiming to reach an agreement with the Department of Health and Social Care (DHSC) and NHS England (NHSE) on negotiation
with regards to expanded services and payment model in the pharmacy sector.
Chief Executive Janet Morrison, said: "We are working at pace in negotiations with DHSC and NHSE. The process remains on track with the Government's original
timescale - i.e. aiming for agreement in July, with cross-government clearance later in July, and implementation from July through to September."
CPE is involved in working groups on service expansion of Hypertension Case-Finding and the Pharmacy Contraception Scheme and service design for the Common
Conditions Service; and are in in-depth negotiations on Payment models.
These discussions critically look at the balance between funding core capacity and activity payments, how the funding streams will be distributed and how CPE
will measure delivery and impact.
NHSE has been leading on the development of the PGD pathways for each of the 7 conditions, with external medical, pharmacy and other experts feeding into the
process - pharmacy owners from the Community Pharmacy England Committee have also been involved but the discussions are clinically led to ensure they comply with
NICE principles and concur with Antimicrobial Stewardship policy.
Community Pharmacy England (CPE) CEO, Janet Morrison said that the negotiations for the £645 million investment pledged to community pharmacies in 2023-25
have concluded.
The government's primary care recovery plan is to be announced in a "few weeks" and negotiations for the Community Pharmacy Contractual Framework (CPCF) from April
2024 will begin.
She said: "We have finished the substantive discussions on the recovery plan but detailed discussions about implementation are ongoing and we are awaiting final
clearance from the Government and the NHS.
"We hope that we will be in a position to make an announcement in the next few weeks and that negotiations on the CPCF from April 2024 will commence soon after
that."
Morrison reminded attendees that the Primary Care Recovery Plan is "to improve access to primary care by investing £645 million over the remainder of the year".
After a series of internal pay negotiations and conciliation meetings, Boots has made a revised pay offer to its pharmacists.
With the new development, the Pharmacists' Defence Association (PDA) has urged its members at Boots to "urgently respond to the Boots pay negotiations update survey on the current pay offer."
It encouraged the members to complete the short survey sent to them via email.
Last week, the PDA Reps Network in Boots hosted a series of virtual meetings for members that work at the company.
As the element of the negotiations with Advisory, Conciliation and Arbitration Service (ACAS) are ongoing, PDA could not provide more details about these meetings.
The tripartite negotiations to set the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2022/23 - Year 4 of the five-year CPCF deal - have now begun, the Pharmaceutical Services Negotiating Committee (PSNC) said.
The discussions, beginning ahead of the start of the financial year, are taking place between the PSNC and the Department of Health and Social Care (DHSC) and the NHS England and NHS Improvement (NHSE&I).
It will cover issues related to service, funding and other arrangements for pharmacies in 2022/23, in line with the five-year CPCF deal.
The three entities will also discuss the progress made to date, which has been partly impacted by the Covid-19 pandemic, and the recent joint Annual Review process, where PSNC raised serious concerns around the available capacity within community pharmacy.
The Royal College of Nursing (RCN) has expressed "extreme disappointment" that the UK government offered new pay to NHS consultants, while nursing pay deal
remain disputed.
RCN General Secretary and Chief Executive Pat Cullen has written to new Health Secretary Victoria Atkins demanding fresh negotiations regarding this year's pay
deal, and requested an urgent meeting to discuss their dispute.
Pat warned that more than 100,000 RCN members in England voted for continued strike action in June, as they feel undervalued.
"The government has now shown it has the political will to negotiate on pay reform for some of the highest earners in the NHS in contrast to our members who
received the lowest pay rise in the public sector," she wrote in the letter.
NHS nursing staff in England was awarded a five per cent pay rise 2023/24, but the union argued that it is not enough to keep up with inflation.
The Pharmaceutical Services Negotiating Committee (PSNC) has advised pharmacy contractors to use emergency provisions to avoid and reduce temporary closures amid shortage of pharmacists and other staff.
The provision was introduced at the start of the pandemic to enables flexible provision of pharmaceutical services by pharmacies.
It has been extended several times, currently until January 31, 2022.
The negotiator noted that self-isolation requirements and a lack of available pharmacists led to a spike in short-notice closures/late opening/early closing incidents in the community pharmacy sector.
However, it reminded contractors that they have a clear duty to provide services in line with their contractual arrangements.
Pharmaceutical Services Negotiating Committee (PSNC) has launched two surveys to gather data on the pressures that people working in community pharmacies are facing.
Pharmacy teams have informed the negotiator about the ongoing financial and operational pressures and expressed concerns that these pressures could impact patients' care.
The surveys would give a snapshot of the problems faced by pharmacies and the results will be used in ongoing discussions with NHS England & NHS Improvement and the Department of Health and Social Care.
The results will also help PSNC to make pharmacy's case in conversations with the MPs, ministers and the national media.
The two separate surveys are for:
Pharmacy business owners/head office representatives - This survey covers the pressures faced by businesses, including financial and staffing pressures.
Pharmacy teams - It covers the day-to-day pressures experienced by pharmacy teams including supply chain issues, patient interactions/experience and staff morale.
The Pharmaceutical Services Negotiating Committee (PSNC) is encouraging community pharmacy contractors to participate in its third Pharmacy Advice Audit due
to be held in the week commencing Monday (January 31).
The audit is aimed to demonstrate how pharmacies support their communities every day and assist PSNC in gathering evidence for use in the funding discussions with the government and the NHS.
It said that last year's Advice Audit provided compelling evidence for use in negotiations with the government and helped in persuading MPs to support the case for Covid-19 costs.
PSNC said: "We would therefore be very grateful to anyone able to take part in this year's audit."
Despite the government's announcement on lifting most Covid-19 related restrictions from next Thursday (January 27), people working in community pharmacies
will be required to adhere to the UK Health Security Agency's infection prevention control (IPC) guidance.
The ambit the guidance, which aims to protect everyone against the infection, also covers GP practices, dental practices and optometry practices, the Pharmaceutical
Services Negotiating Committee said in an update.
The negotiators also urged community pharmacy teams to encourage patients to wear a face covering while vising pharmacy to keep staff and other patients safe.
Prime minister Boris Johnson announced on Wednesday (January 19) that Covid-19 restrictions re-imposed in England last month would be lifted by from next Thursday
(January 27).